The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report

BackgroundDocetaxel combined with prednisone plus androgen deprivation therapy (ADT) is the preferred treatment option for metastatic hormone-sensitive prostate cancer (mHSPC) or metastatic castration-resistant prostate cancer (mCRPC). With the development of next-generation hormonal agents (NHAs) a...

詳細記述

書誌詳細

出版年:	Frontiers in Oncology
主要な著者:	Wei Ning, Pengkang Chang, Ji Zheng, Fan He
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-09-01
主題:	prostate cancer (PCa) metastatic castration-resistant prostate cancer (mCRPC) second docetaxel rechallenge (DR) later-line treatment case report
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1185530/full